Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.35 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment. 
Via Benzinga
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy ↗
The update comes as Sarepta faces mounting regulatory scrutiny, including an ongoing FDA investigation and a recommendation from European regulators to reject approval of Elevidys. 
Via Stocktwits
Topics Death
News headline image
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement ↗
Via Stocktwits
News headline image
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
News headline image
Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback ↗
Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward. 
Via Stocktwits
Topics Death
News headline image
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗
Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys. 
Via Investor's Business Daily
Topics Death
News headline image
Sarepta Therapeutics, Inc. Class Action: Levi &amp; Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Friday's pre-market session: top gainers and losers ↗
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies. ↗
Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues. 
Via Investor's Business Daily
Topics Death Workforce
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Sarepta Therapeutics, Inc. Class Action: Levi &amp; Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Is This Stock a Buy After Soaring by 20% in 1 Day? ↗
Via The Motley Fool
Topics Death
News headline image
Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label ↗
Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and valuation cuts. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Levi &amp; Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division ↗
George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and drug advertising rules. 
Via Benzinga
News headline image
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Sarepta Tumbles On The 'Painful' Decision To Stop Selling Elevidys ↗
Sarepta stock toppled Tuesday after the company said it would voluntarily stop all shipments of Elevidys. 
Via Investor's Business Daily
Topics Death ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.